Funded Project Details - FY2021
|Title:|| PCSK9-A novel target for the treatment of myocardial ischemia|
Jawahar L. Mehta
||Little Rock, AR
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Mainly expressed in liver, kidney and small intestine, the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein-cholesterol receptor (LDLr), and causes degradation of LDLs. Although not proven, it has been suggested that these agents may reduce cardiovascular events. Recent work from our group shows that besides the liver, kidney and small intestine, cardiomyocytes also express PCSK9. The secretion of PCSK9 increases during ischemia by >10 fold. PCSK9...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.